Previous Close | 0.0191 |
Open | 0.0161 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0161 - 0.0192 |
52 Week Range | 0.0117 - 0.0275 |
Volume | |
Avg. Volume | 84,990 |
Market Cap | 9.91M |
Beta (5Y Monthly) | 1.19 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0040 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Vancouver, British Columbia--(Newsfile Corp. - May 9, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce that the British Journal of Pharmacology (the "BJP"), published an article on April 29, 2022, on the design and development of its non-addictive analgesic program ("Analgesic Program") under the running title, "Short dynorphin-like peptide agonists for kappa opioid receptors" click here to see the report. The art
Vancouver, British Columbia--(Newsfile Corp. - March 30, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical") announces that it has issued 11,600,000 common shares without par value in its capital (each, a "Share") to two non-arm's length creditors and an arm's length creditor of the Company at a deemed issuance price of $0.025 per Share.The Company entered into shares for debt settlement agreements with a current director and ...
Vancouver, British Columbia--(Newsfile Corp. - January 13, 2022) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce the settlement of the proposed class action filed by Michael Tietz and Duane Loewen against the Company and many other parties in B.C. Supreme Court Action No. S197731, Vancouver Registry (the "Action").PreveCeutical commenced its own action against some of the defendants to the Action claiming damages for f